1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding Reports Financial Results For Third Quarter 2023

MARKN.

Today, on 25 October 2023, Magle Chemoswed Holding AB (publ) has published its interim report for Q3 2023.

Q3 2023 KEY INDICATORS

  • Net sales amounted to 36.3 MSEK (34.1)
  • EBITDA equalled 4.8 MSEK (4.8)
  • Operating profit (EBIT) is 1.5 MSEK (1.4)
  • Profit after tax amounted to 0.5 MSEK (1.2)
  • Earnings per share SEK 0,1 (0,1) per share

JAN-SEPT 2023 KEY INDICATORS

  • Net sales amounted to 113.1 MSEK (99.8)
  • EBITDA equalled 21.8 MSEK (20.1)
  • Operating profit (EBIT) is 12.1 MSEK (10.1)
  • Profit after tax amounted to 8.1 MSEK (9.1)
  • Earnings per share SEK 0,8 (0,8) per share

“Magle Group has made yet another strong quarter, both in terms of revenue and profit. Total revenues from our CDMO business and DSM-based products increased by 6.7% percent compared to last year’s corresponding period, which is well within our expectations. During the quarter, we have taken a major step in our commercialization strategy by signing a worldwide distribution agreement with the global medical device company, Sirtex Medical” says Justin Pierce, CEO

The full report is available at https://maglegroup.com/financial-reports/

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

Interim Report Q3 2023 MagleGroup

Datum 2023-10-25, kl 08:30
Källa MFN
Bifogade filer
Interim Report Q3 2023 MagleGroup
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!